Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk

Journal of Pediatrics

Volumn 167, Issue 2, 2015, Pages 338-343.e5

  Braamskamp, Marjet J A M ^a   Stefanutti, Claudia ^b   Langslet, Gisle ^c   Drogari, Euridiki ^d   Wiegman, Albert ^a   Hounslow, Neil ^e   Kastelein, John J P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b POLICLINICO UMBERTO I   (Italy)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF ATHENS   (Greece)

^e Kowa Research Europe Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PLACEBO; TRIACYLGLYCEROL; APOLIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; QUINOLINE DERIVATIVE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADOLESCENT; ADRENAL FUNCTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR RISK; CHILD; CHILD SAFETY; CHOLESTEROL BLOOD LEVEL; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FEMALE; GENETIC SCREENING; HEADACHE; HUMAN; HYPERLIPIDEMIA; KIDNEY FUNCTION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MYALGIA; NEUROLOGIC DISEASE; OPEN STUDY; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCHOOL CHILD; SIDE EFFECT; STEROIDOGENESIS; TRIACYLGLYCEROL BLOOD LEVEL; URINALYSIS; VITAL SIGN; AGE; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; DOSE RESPONSE; EUROPE; HYPERLIPIDEMIAS; RISK FACTOR; TREATMENT OUTCOME;

ADOLESCENT; AGE FACTORS; APOLIPOPROTEINS; CARDIOVASCULAR DISEASES; CHILD; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; QUINOLINES; RISK FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84937731998     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2015.05.006     Document Type: Article

References (18)

1. C.A. McMahan, S.S. Gidding, G.T. Malcom, R.E. Tracy, J.P. Strong, and H.C. McGill Pathobiological determinants of atherosclerosis in youth risk scores are associated with early and advanced atherosclerosis Pediatrics 118 2006 1447 1455
2. S. Li, W. Chen, S.R. Srinivasan, J. Xu, and G.S. Berenson Relation of childhood obesity/cardiometabolic phenotypes to adult cardiometabolic profile: the Bogalusa Heart Study Am J Epidemiol 176 Suppl 7 2012 S142 S149
3. A. Wiegman, E. de Groot, B.A. Hutten, J. Rodenburg, J. Gort, H.D. Bakker, and et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia Lancet 363 2004 369 370
4. D.M. Kusters, A. Wiegman, J.J.P. Kastelein, and B.A. Hutten Carotid intima-media thickness in children with familial hypercholesterolemia Circ Res 114 2014 307 310
5. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report Pediatrics 128 Suppl 5 2011 S213 S256
6. S.T. Duggan Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia Drugs 72 2012 565 584
7. L. Ose, D. Budinski, N. Hounslow, and V. Arneson Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia Curr Med Res Opin 25 2009 2755 2764
8. L. Ose, D. Budinski, N. Hounslow, and V. Arneson Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia Atherosclerosis 210 2010 202 208
9. M. Eriksson, D. Budinski, and N. Hounslow Long-term efficacy of pitavastatin versus simvastatin Adv Ther 28 2011 799 810
10. J. Gumprecht, M. Gosho, D. Budinski, and N. Hounslow Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia Diabetes Obes Metab 13 2011 1047 1055
11. M. Eriksson, D. Budinski, and N. Hounslow Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial Adv Ther 28 2011 811 823
12. K. Yokote, H. Shimano, M. Urashima, and T. Teramoto Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis Expert Rev Cardiovasc Ther 9 2011 555 562
13. C. Baigent, A. Keech, P.M. Kearney, L. Blackwell, G. Buck, C. Pollicino, and et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
14. S. De Jongh, L. Ose, T. Szamosi, C. Gagné, M. Lambert, R. Scott, and et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin Circulation 106 2002 2231 2237
15. B.W. McCrindle, L. Ose, and A.D. Marais Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial J Pediatr 143 2003 74 80
16. A. Wiegman, B.A. Hutten, E. de Groot, J. Rodenburg, H.D. Bakker, H.R. Büller, and et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial JAMA 292 2004 331 337
17. H.J. Avis, B.A. Hutten, C. Gagné, G. Langslet, B.W. McCrindle, A. Wiegman, and et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia J Am Coll Cardiol 55 2010 1121 1126
18. B.G. Nordestgaard, M.J. Chapman, S.E. Humphries, H.N. Ginsberg, L. Masana, O.S. Descamps, and et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society Eur Heart J 34 2013 3478 3490a